Initiate a Phase 1 clinical trial of BEAM-103
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 25 Feb 2025
- Due
- 31 Dec 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The company expects to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103, the ESCAPE monoclonal antibody, by the end of 2025.”
What we found
Evidence strength A What the grades mean
The company confirmed in filings dated early 2026 that the Phase 1 clinical trial of BEAM-103 was already ongoing, indicating it was initiated by the end of 2025.
-
A Beam Therapeutics Inc. 10-K filed 2026-02-24
“The ongoing Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE, is expected to complete dosing in the first half of 2026.” ✓ confirmed on the page
Market reaction: the shares moved +1.1% against the S&P 500 over the three sessions around the disclosure (23 Feb 2026 to 26 Feb 2026). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +181 days
- 2 versions
-
Version 1 · original · stated 25 Feb 2025
Deadline 31 Dec 2025 (“by the end of 2025”) · wording expected
-
Version 2 · stated 24 Feb 2026
Deadline 30 Jun 2026 (“in the first half of 2026”) · wording expected
“The ongoing Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE, is expected to complete dosing in the first half of 2026.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- BEAM-103 Phase 1 trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-BEAM-003303 · Corrections policy